Details
Stereochemistry | RACEMIC |
Molecular Formula | C23H25N5O5.ClH |
Molecular Weight | 487.936 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.COC1=CC2=NC(=NC(N)=C2C=C1OC)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4
InChI
InChIKey=AQAZIYFEPYHLHC-UHFFFAOYSA-N
InChI=1S/C23H25N5O5.ClH/c1-30-18-11-14-15(12-19(18)31-2)25-23(26-21(14)24)28-9-7-27(8-10-28)22(29)20-13-32-16-5-3-4-6-17(16)33-20;/h3-6,11-12,20H,7-10,13H2,1-2H3,(H2,24,25,26);1H
Molecular Formula | C23H25N5O5 |
Molecular Weight | 451.4751 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Doxazosin mesylate is a quinazoline compound sold by Pfizer under the brand name CARDURA. CARDURA is indicated for the treatment of both the
urinary outflow obstruction and obstructive and irritative symptoms associated with BPH: obstructive symptoms (hesitation, intermittency, dribbling, weak urinary stream, incomplete emptying of the bladder) and irritative symptoms (nocturia, daytime frequency, urgency, burning). CARDURA may be used in all BPH patients whether hypertensive or normotensive. In
patients with hypertension and BPH, both conditions were effectively treated with CARDURA monotherapy. CARDURA provides rapid improvement in symptoms and urinary flow rate in 66–71% of patients. CARDURA is also indicated for the treatment of hypertension. CARDURA
may be used alone or in combination with diuretics, beta-adrenergic blocking agents, calcium channel blockers, or angiotensin-converting enzyme inhibitors. Doxazosin acts by inhibiting the postsynaptic alpha(1)-adrenoceptors on vascular smooth muscle. This inhibits the vasoconstrictor effect of circulating and locally released catecholamines (epinephrine and norepinephrine), resulting in peripheral vasodilation.
Originator
Sources: http://adisinsight.springer.com/drugs/800010345
Curator's Comment: # Pfizer
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
9.27 null [pKi] | |||
9.09 null [pKi] | |||
9.09 null [pKi] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | CARDURA Approved UseINDICATIONS AND USAGE
A. Benign Prostatic Hyperplasia (BPH). CARDURA is indicated for the treatment of both the
urinary outflow obstruction and obstructive and irritative symptoms associated with BPH:
obstructive symptoms (hesitation, intermittency, dribbling, weak urinary stream, incomplete
emptying of the bladder) and irritative symptoms (nocturia, daytime frequency, urgency,
burning). CARDURA may be used in all BPH patients whether hypertensive or normotensive. In
patients with hypertension and BPH, both conditions were effectively treated with CARDURA
monotherapy. CARDURA provides rapid improvement in symptoms and urinary flow rate in
66–71% of patients. Sustained improvements with CARDURA were seen in patients treated for
up to 14 weeks in double-blind studies and up to 2 years in open-label studies.
B. Hypertension. CARDURA is also indicated for the treatment of hypertension. CARDURA
may be used alone or in combination with diuretics, beta-adrenergic blocking agents, calcium
channel blockers, or angiotensin-converting enzyme inhibitors. Launch Date6.5750401E11 |
|||
Primary | CARDURA Approved UseINDICATIONS AND USAGE
A. Benign Prostatic Hyperplasia (BPH). CARDURA is indicated for the treatment of both the
urinary outflow obstruction and obstructive and irritative symptoms associated with BPH:
obstructive symptoms (hesitation, intermittency, dribbling, weak urinary stream, incomplete
emptying of the bladder) and irritative symptoms (nocturia, daytime frequency, urgency,
burning). CARDURA may be used in all BPH patients whether hypertensive or normotensive. In
patients with hypertension and BPH, both conditions were effectively treated with CARDURA
monotherapy. CARDURA provides rapid improvement in symptoms and urinary flow rate in
66–71% of patients. Sustained improvements with CARDURA were seen in patients treated for
up to 14 weeks in double-blind studies and up to 2 years in open-label studies.
B. Hypertension. CARDURA is also indicated for the treatment of hypertension. CARDURA
may be used alone or in combination with diuretics, beta-adrenergic blocking agents, calcium
channel blockers, or angiotensin-converting enzyme inhibitors. Launch Date6.5750401E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
9.7 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2139337/ |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
DOXAZOSIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
13.6 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2139337/ |
1 mg 1 times / day steady-state, oral dose: 1 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DOXAZOSIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
14.3 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2951261/ |
1 mg 1 times / day steady-state, oral dose: 1 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DOXAZOSIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
151.7 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2951261/ |
16 mg 1 times / day steady-state, oral dose: 16 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DOXAZOSIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
42.3 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2951261/ |
4 mg 1 times / day steady-state, oral dose: 4 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DOXAZOSIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
65.5 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2951261/ |
8 mg 1 times / day steady-state, oral dose: 8 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DOXAZOSIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
162 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2139337/ |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
DOXAZOSIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
268 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2139337/ |
1 mg 1 times / day steady-state, oral dose: 1 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DOXAZOSIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
12.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2139337/ |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
DOXAZOSIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
15 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2139337/ |
1 mg 1 times / day steady-state, oral dose: 1 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DOXAZOSIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
11.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2951261/ |
1 mg 1 times / day steady-state, oral dose: 1 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DOXAZOSIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
11.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2951261/ |
16 mg 1 times / day steady-state, oral dose: 16 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DOXAZOSIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
12.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2951261/ |
4 mg 1 times / day steady-state, oral dose: 4 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DOXAZOSIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
8.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2951261/ |
8 mg 1 times / day steady-state, oral dose: 8 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DOXAZOSIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
60 mg single, oral Overdose |
healthy, 19 years n = 1 Health Status: healthy Age Group: 19 years Sex: F Population Size: 1 Sources: |
Disc. AE: Sinus tachycardia... AEs leading to discontinuation/dose reduction: Sinus tachycardia (1 patient) Sources: |
16 mg single, oral (max) Highest studied dose Dose: 16 mg Route: oral Route: single Dose: 16 mg Sources: |
unhealthy, adult n = 665 Health Status: unhealthy Condition: Hypertension Age Group: adult Sex: unknown Population Size: 665 Sources: |
DLT: Postural edema... Dose limiting toxicities: Postural edema (2.7%) Sources: |
4 mg 1 times / day steady, oral Recommended Dose: 4 mg, 1 times / day Route: oral Route: steady Dose: 4 mg, 1 times / day Sources: |
healthy, adult n = 35 Health Status: healthy Age Group: adult Sex: unknown Population Size: 35 Sources: |
Disc. AE: Orthostatic dizziness... AEs leading to discontinuation/dose reduction: Orthostatic dizziness (1 patient) Sources: |
16 mg 1 times / day steady, oral (max) Highest studied dose Dose: 16 mg, 1 times / day Route: oral Route: steady Dose: 16 mg, 1 times / day Sources: |
unhealthy, mean 59 years n = 97 Health Status: unhealthy Condition: Hypertension Age Group: mean 59 years Sex: M+F Population Size: 97 Sources: |
Disc. AE: Fatigue, Urinary incontinence... Other AEs: Rhinitis... AEs leading to discontinuation/dose reduction: Fatigue (3 patients) Other AEs:Urinary incontinence (2 patients) Rhinitis (1 patient) Sources: |
8 mg 1 times / day steady, oral Dose: 8 mg, 1 times / day Route: oral Route: steady Dose: 8 mg, 1 times / day Sources: |
unhealthy n = 22 Health Status: unhealthy Condition: cocaine dependence Population Size: 22 Sources: |
Other AEs: Nausea, Constipation... Other AEs: Nausea (below serious, 2 patients) Sources: Constipation (below serious, 1 patient) Allergy (below serious, 1 patient) Dizziness (below serious, 1 patient) Numbness (below serious, 1 patient) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Sinus tachycardia | 1 patient Disc. AE |
60 mg single, oral Overdose |
healthy, 19 years n = 1 Health Status: healthy Age Group: 19 years Sex: F Population Size: 1 Sources: |
Postural edema | 2.7% DLT |
16 mg single, oral (max) Highest studied dose Dose: 16 mg Route: oral Route: single Dose: 16 mg Sources: |
unhealthy, adult n = 665 Health Status: unhealthy Condition: Hypertension Age Group: adult Sex: unknown Population Size: 665 Sources: |
Orthostatic dizziness | 1 patient Disc. AE |
4 mg 1 times / day steady, oral Recommended Dose: 4 mg, 1 times / day Route: oral Route: steady Dose: 4 mg, 1 times / day Sources: |
healthy, adult n = 35 Health Status: healthy Age Group: adult Sex: unknown Population Size: 35 Sources: |
Rhinitis | 1 patient | 16 mg 1 times / day steady, oral (max) Highest studied dose Dose: 16 mg, 1 times / day Route: oral Route: steady Dose: 16 mg, 1 times / day Sources: |
unhealthy, mean 59 years n = 97 Health Status: unhealthy Condition: Hypertension Age Group: mean 59 years Sex: M+F Population Size: 97 Sources: |
Urinary incontinence | 2 patients Disc. AE |
16 mg 1 times / day steady, oral (max) Highest studied dose Dose: 16 mg, 1 times / day Route: oral Route: steady Dose: 16 mg, 1 times / day Sources: |
unhealthy, mean 59 years n = 97 Health Status: unhealthy Condition: Hypertension Age Group: mean 59 years Sex: M+F Population Size: 97 Sources: |
Fatigue | 3 patients Disc. AE |
16 mg 1 times / day steady, oral (max) Highest studied dose Dose: 16 mg, 1 times / day Route: oral Route: steady Dose: 16 mg, 1 times / day Sources: |
unhealthy, mean 59 years n = 97 Health Status: unhealthy Condition: Hypertension Age Group: mean 59 years Sex: M+F Population Size: 97 Sources: |
Allergy | below serious, 1 patient | 8 mg 1 times / day steady, oral Dose: 8 mg, 1 times / day Route: oral Route: steady Dose: 8 mg, 1 times / day Sources: |
unhealthy n = 22 Health Status: unhealthy Condition: cocaine dependence Population Size: 22 Sources: |
Constipation | below serious, 1 patient | 8 mg 1 times / day steady, oral Dose: 8 mg, 1 times / day Route: oral Route: steady Dose: 8 mg, 1 times / day Sources: |
unhealthy n = 22 Health Status: unhealthy Condition: cocaine dependence Population Size: 22 Sources: |
Dizziness | below serious, 1 patient | 8 mg 1 times / day steady, oral Dose: 8 mg, 1 times / day Route: oral Route: steady Dose: 8 mg, 1 times / day Sources: |
unhealthy n = 22 Health Status: unhealthy Condition: cocaine dependence Population Size: 22 Sources: |
Numbness | below serious, 1 patient | 8 mg 1 times / day steady, oral Dose: 8 mg, 1 times / day Route: oral Route: steady Dose: 8 mg, 1 times / day Sources: |
unhealthy n = 22 Health Status: unhealthy Condition: cocaine dependence Population Size: 22 Sources: |
Nausea | below serious, 2 patients | 8 mg 1 times / day steady, oral Dose: 8 mg, 1 times / day Route: oral Route: steady Dose: 8 mg, 1 times / day Sources: |
unhealthy n = 22 Health Status: unhealthy Condition: cocaine dependence Population Size: 22 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no | ||||
no | ||||
no | ||||
yes | ||||
yes | ||||
yes | ||||
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
major | likely (co-administration study) Comment: Boceprevir may increase doxazosin concentrations through CYP3A inhibition |
|||
minor | ||||
minor | ||||
minor |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Effects of two atypical neuroleptics, olanzapine and risperidone, on the function of the urinary bladder and the external urethral sphincter in anesthetized rats. | 2001 |
|
Is postural hypotension a real problem with antihypertensive medication? | 2001 |
|
A comparison of selected antihypertensives and the use of conventional vs ambulatory blood pressure in the detection and treatment of hypertension. | 2001 |
|
Lessons learned from prematurely terminated clinical trials. | 2001 Aug |
|
Meta-analysis of studies using selective alpha1-blockers in patients with hypertension and type 2 diabetes. | 2001 Dec |
|
5alpha-reductase inhibitors: what role should they play? | 2001 Dec |
|
Terazosin, doxazosin, and prazosin: current clinical experience. | 2001 Dec |
|
Tamsulosin: current clinical experience. | 2001 Dec |
|
Clinical Implications of Recent Findings from the Antihypertensive and Lipid-Lowering Treatment To Prevent Heart Attack Trial (ALLHAT) and Other Studies of Hypertension. | 2001 Dec 18 |
|
On call. I'm a 76-year-old man with an enlarged prostate. I've been taking Cardura and it's helped a lot, but my doctor stopped it because he said a study found the drug could cause heart failure. Now I'm getting up three or four times a night again. Is Cadura safe? | 2001 Jul |
|
Antihypertensive effect of alpha- and beta-adrenergic blockade in obese and lean hypertensive subjects. | 2001 Jul |
|
[Doxazosin and soluble guanylate cyclase in a rat model of hypertension]. | 2001 Jul |
|
Reduction of human prostate tumor vascularity by the alpha1-adrenoceptor antagonist terazosin. | 2001 Jul 1 |
|
Low-dose alpha/beta blockade in the treatment of essential hypertension. | 2001 Jun |
|
Voltammetric determination of doxazosin in tablets using rotating platinum electrode. | 2001 Jun |
|
US FDA weighs options for warning on antihypertensive drug. | 2001 Jun 2 |
|
Structure-activity studies for a novel series of bicyclic substituted hexahydrobenz[e]isoindole alpha1A adrenoceptor antagonists as potential agents for the symptomatic treatment of benign prostatic hyperplasia. | 2001 Jun 7 |
|
[Long-term therapy of benign prostatic hyperplasia. Our experience]. | 2001 Mar |
|
Apoptotic regression of prostatic tissue induced by short-term doxazosin treatment in benign prostatic hyperplasia. | 2001 Mar |
|
Update in pharmacologic treatment of hypertension. | 2001 May |
|
Initiation of nonselective alpha1-antagonist therapy and occurrence of hypotension-related adverse events among men with benign prostatic hyperplasia: a retrospective cohort study. | 2001 May |
|
Effect of antihypertensive therapy on renal artery structure in type 2 diabetic rats with hypertension. | 2001 May |
|
Reversible renal impairment induced by treatment with the angiotensin II receptor antagonist candesartan in a patient with bilateral renal artery stenosis. | 2001 May 17 |
|
[Alpha-blockers in therapy of arterial hypertension. No longer the drug of first choice]. | 2001 May 31 |
|
Effects of antihypertensive agents on blood pressure during exercise. | 2001 Nov |
|
Doxazosin for the management of hypertension: implications of the findings of the ALLHAT trial. | 2001 Nov |
|
Effects of blood pressure lowering with amlodipine or lisinopril on vascular structure of the common carotid artery. | 2001 Nov |
|
Doxazosin and congestive heart failure. | 2001 Nov 1 |
|
Cardiovascular protection and blood pressure reduction: a meta-analysis. | 2001 Oct 20 |
|
Doxazosin reduces prevalence of small dense low density lipoprotein and remnant-like particle cholesterol levels in nondiabetic and diabetic hypertensive patients. | 2001 Sep |
|
Heart lines. Cardura update. | 2001 Sep |
|
The choice of antihypertensive drugs in patients with erectile dysfunction. | 2002 |
|
Acute effects of serotonin on rat bladder contractility. | 2002 |
|
[Doxazosin, of modified liberation, in hemodialyzed patients]. | 2002 Apr |
|
Double-blind, placebo-controlled crossover comparison of five classes of antihypertensive drugs. | 2002 Apr |
|
Efficacy and safety of doxazosin for perioperative management of patients with pheochromocytoma. | 2002 Aug |
|
Two-drug therapy is best for symptomatic prostate enlargement: combination should change clinical practice. | 2002 Aug |
|
Medical therapy for benign prostatic hyperplasia progression. | 2002 Aug |
|
Critical evaluation of the problem of chronic urinary retention after orthotopic bladder substitution in women. | 2002 Aug |
|
Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. | 2002 Aug 6 |
|
Differential actions of naftopidil, doxazosin and nifedipine on platelet thromboxane generation and platelet-derived growth factor efflux in vitro. | 2002 Aug-Sep |
|
Double-blind, crossover, comparative study of doxazosin and enalapril in the treatment of hypertension in renal transplant patients under cyclosporine immunosuppression. | 2002 Feb |
|
Combined oral therapy with sildenafil and doxazosin for the treatment of non-organic erectile dysfunction refractory to sildenafil monotherapy. | 2002 Feb |
|
Modeling of relationships between pharmacokinetics and blockade of agonist-induced elevation of intraurethral pressure and mean arterial pressure in conscious dogs treated with alpha(1)-adrenoceptor antagonists. | 2002 Feb |
|
Relationship between arterial distensibility and low-frequency power spectrum of blood pressure in spontaneously hypertensive rats. | 2002 Jan |
|
Psychological characteristics and responses to antihypertensive drug therapy. | 2002 Jan-Feb |
|
Treatment of hypertension in the elderly. | 2002 Jan-Feb |
|
Managing benign prostatic hyperplasia. | 2002 Jul 1 |
|
Successful blood pressure control in the African American Study of Kidney Disease and Hypertension. | 2002 Jul 22 |
|
Relationship of antihypertensive treatment regimens and change in blood pressure to risk for heart failure in hypertensive patients randomly assigned to doxazosin or chlorthalidone: further analyses from the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial. | 2002 Sep 3 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/dosage/doxazosin.html
Usual Adult Dose for Hypertension
Initial dose: 1 mg orally once a day.
Maintenance dose: 1 to 16 mg orally once a day.
Usual Adult Dose for Benign Prostatic Hyperplasia
Initial dose:
Immediate-release: 1 mg orally once a day.
Extended-release: 4 mg orally once a day with breakfast
Maintenance dose:
Immediate-release: 1 to 8 mg orally once a day.
Extended-release: 4 to 8 mg orally once a day with breakfast. Depending on the patient's symptomatic response and tolerability, the dose may be increased to 8 mg (the maximum recommended dose). The recommended titration interval is 3 to 4 weeks.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2977161
Ring segments of splanchnic, peripheral, coronary, pulmonary and uterine conduit arteries obtained during surgery were studied in tissue baths. Resistance arteries dissected from various sites were studied in a myograph. Both conduit and resistance vessels contracted in response to the alpha 1-agonist phenylephrine (10(-7) to 10(-4) mol/l), an effect that was antagonized by the alpha 1-antagonist doxazosin (10(-8) to 10(-6) mol/l).
Substance Class |
Chemical
Created
by
admin
on
Edited
Sun Dec 18 07:40:53 UTC 2022
by
admin
on
Sun Dec 18 07:40:53 UTC 2022
|
Record UNII |
Y9EDC2483R
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
70918-01-3
Created by
admin on Sun Dec 18 07:40:53 UTC 2022 , Edited by admin on Sun Dec 18 07:40:53 UTC 2022
|
PRIMARY | |||
|
DTXSID00469077
Created by
admin on Sun Dec 18 07:40:53 UTC 2022 , Edited by admin on Sun Dec 18 07:40:53 UTC 2022
|
PRIMARY | |||
|
Y9EDC2483R
Created by
admin on Sun Dec 18 07:40:53 UTC 2022 , Edited by admin on Sun Dec 18 07:40:53 UTC 2022
|
PRIMARY | |||
|
11591230
Created by
admin on Sun Dec 18 07:40:53 UTC 2022 , Edited by admin on Sun Dec 18 07:40:53 UTC 2022
|
PRIMARY | |||
|
105314-71-4
Created by
admin on Sun Dec 18 07:40:53 UTC 2022 , Edited by admin on Sun Dec 18 07:40:53 UTC 2022
|
NON-SPECIFIC STOICHIOMETRY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |